AI in Dermatology & Beauty Technology
Artificial intelligence is no longer a futuristic concept in medicine, it is already embedded in how dermatologists diagnose disease, how beauty companies develop ingredients, and how patients interact with their skin health. At Beauty Tech Derm, we track the science, the clinical applications, and the regulatory landscape shaping this transformation.
This section is a resource for clinicians, researchers, industry professionals, and informed consumers who want to understand what AI in dermatology and beauty technology actually means, beyond the marketing language.
What AI Is Doing in Dermatology Right Now
Skin Lesion Analysis and Cancer Detection
Convolutional neural networks (CNNs) trained on large dermoscopy datasets can now classify pigmented lesions with accuracy comparable to board-certified dermatologists in controlled studies. AI-assisted dermoscopy tools are being evaluated and, in some cases, cleared by the FDA as decision-support devices, not replacements for physician judgment, but tools that can flag lesions that merit closer attention.
The clinical value is clearest in resource-limited settings and teledermatology, where AI triage can help prioritize which patients need in-person evaluation urgently.
AI-Powered Patient Documentation
AI scribing tools, software that listens to patient-physician conversations and generates structured clinical notes, are entering dermatology practices. Dr. Yoo has evaluated one such system, Suki AI, in a real-world clinical setting. The reduction in documentation burden is meaningful; the limitations are equally important to understand.
Augmented Reality and Skin Visualization
AR-powered skin analysis tools, from consumer apps to in-office devices, use computer vision to assess hydration, texture, pigmentation, and signs of aging. The clinical accuracy of consumer-grade tools varies widely. Understanding the difference between validated clinical systems and consumer-facing products is a core focus of our coverage here.
AI in the Beauty Industry: Innovation and Hype
Beauty companies from L’Oréal to Amorepacific are deploying AI across the product development pipeline, accelerating ingredient discovery, predicting formulation stability, personalizing product recommendations, and powering virtual try-on experiences.
The distinction that matters: AI as a research and development tool (genuinely transformative) versus AI as a marketing label applied to products with minimal algorithmic substance. We cover both, and we are clear about which is which.
Recent coverage includes:
- L’Oréal’s expanded AI partnership with Nvidia for skin science R&D
- Amorepacific’s use of AI and molecular modeling to develop a hair-strengthening peptide
- Shiseido’s AI-driven ingredient safety and biodegradability prediction systems
Bias, Equity, and AI in Skin of Color
AI systems trained on non-representative datasets perform unevenly across skin tones, ethnicities, and demographics. In dermatology, this has direct clinical consequences, diagnostic algorithms that underperform on darker skin tones can contribute to delayed diagnoses and health disparities.
This is not a peripheral issue. Addressing algorithmic bias in beauty and medical AI is a prerequisite for these technologies to deliver equitable benefit. Dr. Yoo has been active in skin of color dermatology through the Skin of Color Society and Allergan’s Aesthetic Diversity Summit, and brings that lens to the coverage here.
The Regulatory Landscape
AI in healthcare and beauty technology sits at the intersection of multiple regulatory frameworks, the FDA’s Software as a Medical Device (SaMD) pathway in the US, the EU AI Act, and evolving guidelines from agencies in the UK, Australia, Singapore, and beyond.
Understanding these frameworks matters for anyone developing, evaluating, or using AI tools in clinical or cosmetic settings. The pace of regulatory development has accelerated significantly since 2021, and the gap between what AI can do and what has been formally approved or validated remains wide.
About This ResourceBeauty Tech Derm is founded and led by Dr. Jane Yoo, MD, MPP, board-certified dermatologist, fellowship-trained Mohs surgeon, and Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai. Dr. Yoo has published peer-reviewed research on AI in aesthetic dermatology dating to 2012 and lectures internationally on the clinical and regulatory dimensions of AI in medicine, including at IMCAS Paris, AAD, FACE London, and Korea Derma Seoul. Her MIT and Harvard Kennedy School training informs a perspective that is simultaneously scientific, clinical, and policy-oriented, the combination that distinguishes BeautyTechDerm coverage from both academic literature and beauty media. |
Selected Publications
Dr. Yoo’s peer-reviewed work on AI in dermatology includes:
- AI in Aesthetic/Cosmetic Dermatology: Current and Future — Journal of Cosmetic Dermatology
- Assessing the Landscape of AI-Powered Patient Documentation in Dermatology — JDD Online
- Skin and Digital: The 2024 Narrative — Mayo Clinic Proceedings Digital Health
- Assessment of a Diagnostic Predictive Probability Model for Melanoma — PubMed Central
